Biocon announced that the company and it European partner, Zentiva, have received a Decentralized Procedure (DCP) approval for its complex formulation, Liraglutide, in the European Union (EU). The approval is for the generic versions of Victoza to treat Type-2 Diabetes and
Saxenda used in the treatment of weight management.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
